Novo Nordisk Boardroom Clean-Out Is Rare Case of Director Accountability
The Danish drugmaker’s ownership structure creates ‘an unusual opportunity’ for change.
This article is for subscribers only.
Analyzing trends in leadership, company culture and the art of career building. If this newsletter was forwarded to you by a friend or a thoughtful colleague, sign up here to continue receiving it.
Outside of a hostile takeover, it’s rare to see corporate directors defrocked en masse for missteps in strategy or company performance. Usually it’s management that answers for that, if the board is doing its job.